来自MSN1 年
Sanofi shares positive results from trial of frexalimab for MS
French pharmaceutical company Sanofi has announced positive results from a Phase II trial of its investigational anti-CD40L antibody, frexalimab. In the trial, the drug was found to reduce brain ...
pharmaphorum1 年
Sanofi scores in MS with CD40 antibody frexalimab
Sanofi has posted encouraging results with one of its mid-stage candidates for multiple sclerosis, anti-CD40L antibody frexalimab, and says it plans to move the drug into a phase 3 programme next ...